HK Stock Market Move | Simcere Pharma (02096) surged by over 12%, with trading volume exceeding 200 million Hong Kong dollars. The company is expected to welcome multiple catalysts.

SIMCERE PHARMA (02096) rose by more than 12% on high volume. As of the time of writing, it was up 12.38% at 6.99 Hong Kong dollars, with a trading volume of 2.33 billion Hong Kong dollars. On the news front, a recent research report from CICC pointed out that the company's existing business risks have been cleared, making it relatively stable. From October 27 to 30, the National Healthcare Security Administration conducted a new round of healthcare negotiation. The company's core products Xian Bixi has undergone two rounds of price negotiations, and the bank believes that the current single treatment cost is reasonable. The bank expects the two innovative products Koselela (CDK4/6 inhibitor) and Enlituo (EGFR monoclonal antibody) to be included in the healthcare negotiations, and they are expected to see increased sales next year after being included in the healthcare system. The bank predicts that the company's recent innovative drugs expected to be approved are: 1) Xian Bixi sublingual tablets, which are expected to be approved in the next 1-2 months, with the bank estimating potential sales of over 1.5 billion yuan in the future; 2) Enzeshu (VEGF monoclonal antibody for ovarian cancer), expected to be approved in the first half of 2025; 3) Keweike (Dalerleysine) for insomnia, a third-generation dual orexin receptor antagonist, likely to be approved in 2025. In addition, innovative drugs such as Lodequinab monoclonal antibody (IL-4) and Madonoza wei (influenza) are currently in Phase III clinical trials.